Safety, Tolerability, and Pharmacokinetics Study of ATH-1020

A Randomized, Placebo-Controlled, Double-Blinded, First-in-Human, Adaptive Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses (Part A) and Multiple Ascending Doses (Part B) of Orally Administered ATH-1020 in Healthy Young and Elderly Subjects

This Phase 1 randomized, placebo-controlled, double-blinded, first-in-human study will evaluate safety, tolerability, and pharmacokinetics of single and multiple ascending doses of ATH-1020 in healthy young and elderly subjects.

Study Overview

• Status: Completed
• Conditions: Healthy Volunteers
• Intervention / Treatment: Drug: ATH-1020; Drug: Placebo

Detailed Description

This is a Phase 1 first-in-human, 2-part adaptive study. Both Part A and Part B will be performed in a randomized, placebo-controlled, and double-blind manner.

Part A - Single Ascending Dose (SAD) Part A will be a SAD study investigating multiple dose levels of ATH 1020.

Part B - Multiple Ascending Dose (MAD) Part B will be a multiple ascending dose (MAD) study investigating multiple dose levels of ATH-1020.

Subjects in Cohort B5 (4 subjects) will additionally undergo CSF sampling pre-dose on Day 4 and up to 3 post dose timepoints to evaluate ATH-1020 blood-brain-barrier penetration

• Study Type: Interventional
• Enrollment (Actual): 32
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • New Jersey
    • Newark, New Jersey, United States, 07103
      • Biotrial, Inc.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 85 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

All Subjects

1. Body mass index (BMI) of ≥ 18.0 and ≤ 32.0 kg/m2 at Screening, with minimum weight of 60 kg.
2. Subjects in generally good health per the investigator's discretion.
3. Male subjects and their partners must be willing to comply with the contraceptive requirements of the study.

4. Subjects must have adequate venous access.

   Part A (SAD)

5. Male subjects aged 18 to 50 years at the time of signing the informed consent.

   Part B (MAD)

6. Male subjects aged 18 to 50 years (Cohorts B1, B2, B3, and B5); male and post-menopausal female subjects aged 65 to 85 years (Cohort B4) at the time of signing the informed consent.

Exclusion Criteria:

1. History of significant drug allergies (including to any excipients) or of anaphylactic reaction.
2. Any condition per the investigator's discretion, which while not requiring chronic medication use, is likely to require intermittent/acute therapeutic intervention.
3. Any history of seizures or loss of consciousness for an unknown reason.
4. History of or positive results of serology screening for hepatitis B, hepatitis C or human immunodeficiency virus (HIV).
5. Abnormal liver tests
6. Impaired renal function.
7. History of having taken another investigational drug within 30 days prior to Admission (Day -1).

8. Major surgery within 90 days prior to Admission (Day -1) or anticipated surgery during the study.

   Part A (SAD)

9. Female subjects are not permitted.

10. Any medical condition that requires chronic medication use.

    Part B (MAD)

11. A history of intermittent benzodiazepine (short-acting only) or other treatments for insomnia and anxiety are allowed, provided that the subject is able to abstain from their use during the Screening period, and from Admission until discharge from the study.

12. Reported changes in cognition and reported history of declines in everyday life in the last year.

    Part B (MAD) CSF Sampling (Cohort B5)

13. Subject history of or current contraindication to lumbar puncture/spinal catheterization.
14. Clinically significant abnormalities in coagulation parameters.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Sequential Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: ATH-1020; ATH-1020 in oral form. Participants in the single ascending dose cohort (Cohort A) will receive a single dose of ATH-1020. Participants in the multiple ascending dose cohort (Cohort B) will receive up to nine doses of ATH-1020 (up to 4 for cohort B5).	Drug: ATH-1020; ATH-1020 in oral capsule form
Placebo Comparator: Placebo; Placebo in oral form. Participants in the single ascending dose cohort (Cohort A) will receive a single dose of Placebo. Participants in the multiple ascending dose cohort (Cohort B) will receive up to nine doses of placebo.	Drug: Placebo; Placebo in oral capsule form

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)	Safety and tolerability of single or multiple ascending doses of ATH-1020 as measured by vital signs and clinical laboratory measurements.	Up to 12 days post initial dosing (Part A); Up to 19 days post initial dosing (Part B)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum observed plasma concentration (Cmax)	Cmax will be determined from all collected plasma samples from baseline through up to 48 hours post-dose.	Cmax will be determined from all collected plasma samples from baseline through up to 48 hours post-dose.
Time to maximum observed plasma concentration (Tmax)	Tmax will be determined from all collected plasma samples from baseline through up to 48 hours post-dose.	Samples collected pre-dose and at predetermined timepoints within 48 hours post-dose.
Plasma concentration at the end of the dosing interval (Ctrough)	Ctrough will be determined from the last plasma sample prior to the following dose (cohort B only).	Samples collected pre-dose and at predetermined timepoints within 24 hours post-dose.
Area under the plasma concentration time curve (AUC)	AUC will be determined from all collected plasma samples from baseline through up to 48 hours post-dose.	Samples collected pre-dose and at predetermined timepoints within 48 hours post-dose.
Half-life (t1/2)	t1/2 will be determined from all collected plasma samples from baseline through up to 48 hours post-dose.	Samples collected pre-dose and at predetermined timepoints within 48 hours post-dose.
Amount of IMP excreted unchanged in the urine (Ae)	Ae will be determined from all collected urine samples from baseline through up to 24 hours post-dose (cohort B1-4 only).	Samples collected pre-dose on Day 1 and predetermined timepoints on Day 1, 9, and 10, within 24 hours post-dose.

Collaborators and Investigators

• Sponsor: Athira Pharma
• Collaborators: Biotrial Inc.; Alturas Analytics, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): March 30, 2022
• Primary Completion (Actual): September 9, 2022
• Study Completion (Actual): September 9, 2022

Study Registration Dates

• First Submitted: December 6, 2021
• First Submitted That Met QC Criteria: December 10, 2021
• First Posted (Actual): December 27, 2021

Study Record Updates

• Last Update Posted (Actual): April 8, 2024
• Last Update Submitted That Met QC Criteria: April 5, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Keywords: Pharmacokinetics; HGF/MET
• Other Study ID Numbers: ATH-1020-0101

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No